Early Breast Cancer
KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery.
Patients are selected for therapy based on an FDA-approved test for KADCYLA.
Metastatic Breast Cancer
KADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
Patients are selected for therapy based on an FDA-approved test for KADCYLA.
Talk to a healthcare professional for more information about the benefits and risks of KADCYLA.
Please see full Prescribing Information for Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
For more, you can visit
ADCETRIS is a prescription medicine directed against the CD30 protein. It is used to treat:
Adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma, in combination with chemotherapy (Adriamycin, vinblastine, and dacarbazine)
Children 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma, in combination with chemotherapy (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide)
Adults with classical Hodgkin lymphoma at high risk of coming back or becoming worse after a stem cell transplant
Adults with classical Hodgkin lymphoma after a stem cell transplant fails or after at least 2 chemotherapy treatments fail and stem cell transplant is not an option
Adults with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphomas not otherwise specified, in combination with chemotherapy (cyclophosphamide, doxorubicin, and prednisone)
Adults with systemic anaplastic large cell lymphoma after at least 1 combination chemotherapy treatment fails
Adults with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides after systemic therapy (drugs that spread throughout the body)
For more, you can visit
ENHERTU (en-HER-too) is a prescription medicine used to treat adults who have:
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:
o For metastatic disease, or
Have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received a prior chemotherapy:
o For metastatic disease, or
Your disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you.
Non-small cell lung cancer (NSCLC) that has a certain mutation in the HER2 gene and cannot be removed by surgery or has spread to other parts of your body (metastatic), and who have received a prior treatment. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.
Stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that is HER2-positive and has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.
It is not known if ENHERTU is safe and effective in children.
Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide.
For more, you can visit
WHAT IS PADCEV®?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used alone if you:
• have received an immunotherapy medicine and chemotherapy that contains platinum, or
• are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.
PADCEV may be used with pembrolizumab (also known as Keytruda®) if you:
• are not able to receive a chemotherapy that contains the medicine cisplatin.
It is not known if PADCEV is safe and effective in children.
For more, you can visit
www.drugshk.com
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with:
hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who previously received endocrine therapy and at least two additional treatments for metastatic disease
triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
bladder cancer and cancers of the urinary tract that have spread or cannot be removed by surgery, and who have received a platinum-containing chemotherapy medicine and also received an immunotherapy medicine. This indication is approved based on medical studies that measured how many patients responded and how long they responded. Continued approval may depend on benefit demonstrated in additional medical studies.
It is not known if TRODELVY is safe and effective in people with moderate or severe liver problems or in children.
For more, you can visit
POLIVY is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL).
POLIVY is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat DLBCL in adults who have progressed after at least 2 prior therapies.
For more, you can visit
https://www.polivy.com/newly-diagnosed/rchp.html
BESPONSA® (inotuzumab ozogamicin) is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
For more, you can visit:
TIVDAK is a prescription medicine used to treat adults with cervical cancer:
· that has returned or has spread to other parts of the body, and
· who have received chemotherapy that did not work or is no longer working
TIVDAK was FDA-approved based on a clinical study that measured how many patients had a tumor response and how long that response lasted. Continued approval is dependent on the results of an ongoing study to confirm the benefit of TIVDAK.
For more, you can visit:
MYLOTARG is indicated for the treatment of
Newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older
Relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older
For more, you can visit:
https://mylotarg.pfizerpro.com/
ZYNLONTA® is a prescription medicine used to treat adults with certain types of large B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), who have already received two or more treatments for their cancer.
It is not known if ZYNLONTA® is safe and effective in children.
The approval of ZYNLONTA® is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of ZYNLONTA®.
For more, you can visit:
ELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who:
have not responded to or are no longer responding to treatment with platinum-based chemotherapy and
· have received 1 to 3 prior types of chemotherapy.
Your healthcare provider will perform a test to make sure that ELAHERE is right for you.
ELAHERE was FDA-approved based on a clinical study that measured how many patients had a tumor response and how long that response lasted. Continued approval is dependent on the results of an ongoing study to confirm the benefit of ELAHERE.
For more, you can visit:
https://www.elahere.com/
